Comparing two ways to treat an overactive thyroid in Graves' eye disease
Compares thyroid medicines with radioiodine or surgery in Graves' disease with active eye involvement.
Key facts
- Who runs it
- Azienda Ospedaliero Universitaria Pisana
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Registry title
- A phase III, randomized, controlled, open label, no profit, single-center intervention study to compare the effect of a conservative (antithyroid drugs) and an ablative approach (radioiodine or total thyroidectomy) for the treatment of hyperthyroidism in patients with Graves’ disease and moderate-to-severe and active Graves’ Orbitopathy (GO) treated with intravenous glucocorticoids (ABLAGO Study)
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 52 people, planned
- Started
- 20 Mar 2023
- Planned end
- 20 Mar 2026
- Type of study
- Interventional
- Record updated
- 19 November 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Graves' disease and moderate-to-severe, active Graves' eye disease (Graves' Orbitopathy) who will get intravenous glucocorticoids. It compares antithyroid drugs with radioiodine or thyroid removal surgery.
- Age
- 18-75 years
- Sex
- Men and women
- Disease stage
- Graves' disease for less than 18 months, with normal thyroid levels on stable medicine. Moderate-to-severe, active eye disease (CAS ≥ 3 out of 7) for less than 18 months, with at least two signs such as bulging eye ≥3 mm, double vision or lid retraction ≥2 mm.
- Earlier treatment
- No earlier radioiodine or thyroid surgery for Graves' disease. No corticosteroids or other immune-suppressing treatment in the last 3 months. No earlier eye surgery or radiotherapy for the eye disease.
- Biomarker or test result
- Detectable TSH receptor autoantibodies (TRAb). AST, ALT and CPK ≤ 3 times the upper normal value. Neutrophil count >1000 cells/L.
Main reasons for not taking part
- Eye disease that damages the optic nerve or threatens sight
- Reasons you cannot have glucocorticoids, radioiodine, MMI or thyroid surgery
- Acute or chronic liver disease
- Relevant cancer, or alcohol or drug abuse in the last 1 year
- Pregnancy or breastfeeding
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Patients willing and capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form 2. A diagnosis of Graves’ disease based on the presence of hyperthyroidism associated with detectable anti-thyrotropic hormone (TSH) receptor autoantibodies (TRAb). Patients must be euthyroid under control on stable medical regimen and every effort will be made to maintain the euthyroid status for the entire duration of the clinical trial. 3. Duration of Graves’ disease shorter than 18 months 4. A moderate-to-severe GO, defined as the presence of at least two of the following criteria in the most affected eye: an exophthalmos ≥3 mm compared with normal values for sex and race; presence of inconstant to constant diplopia; a lid retraction ≥2 mm; active GO (see below) 5. Active GO: CAS ≥ 3 out of 7 points in the most affected eye. Taking into account severity (moderate-to-severe) and activity (CAS ≥ 3/7) of GO, patients are eligible for methylprednisolone treatment according to clinical practice. 6. Duration of GO shorter than 18 months 7. AST, ALT and CPK levels ≤ 3 times the upper value of normal range 8. Absolute neutrophil count >1000 cells/L 9. Women of childbearing potential (WOCBP, namely not in menopause or in menopause since less than two years; in all other instances women will be considered as non-WOCBP) and men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year (as indicated in Appendix) for at least 6 and 7,5 months, respectively, after the last dose of the investigational drug (see also 2014_09_HMA_CTFG_Contraception.pdf, namely the “2014 CTFG Recommendations related to contraception and pregnancy testing in clinical trials”) 10. Male and female patients of age 18-75 years
Who cannot take part
- Optic neuropathy or sight threatening GO of any type 2. Previous therapy for Graves’ disease with radioiodine or thyroidectomy 3. Corticosteroids or other immunosuppressive treatment for GO or other reasons in the last 3 months. 4. Previous surgical treatment and/or radiotherapy for GO. 5. Contraindications to GC: hypersensitivity to the active substance or to any of the excipients; uncontrolled hypertension, uncontrolled diabetes; history of peptic ulcer; urinary infections, glaucoma, systemic fungal infections, systemic infections unless appropriate therapy is employed, idiopathic thrombocytopenic purpura, cerebral edema associated with malaria. 6. Contraindications to RAI. 7. Previous or current glucocorticoid-related psychosis. 8. Use of medications interfering with GC or increasing the risk of GC-related adverse events (see prohibited therapies) 9. Acute or chronic liver disease 10. Contraindications to MMI: hypersensitivity to the active substance or to any of the excipients; breastfeeding 11. Contraindications of any kind to perform thyroidectomy 12. Relevant Malignancy 13. Recent (≤1 year) history of alcoholism or drug abuse 14. Mental illness that prevent patients from comprehensive, written informed consent 15. Pregnancy or breastfeeding
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To compare the effects of a conservative approach (antithyroid drugs, ATDs, experimental arm) vs an ablative approach (radioiodine or total thyroidectomy) of thyroid treatment on the overall outcome of GO in patients with GD and moderate-to-severe and active GO treated with intravenous glucocorticoids at 24 weeks.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A phase III, randomized, controlled, open label, no profit, single-center intervention study to compare the effect of a conservative (antithyroid drugs) and an ablative approach (radioiodine or total thyroidectomy) for the treatment of hyperthyroidism in patients with Graves’ disease and moderate-to-severe and active Graves’ Orbitopathy (GO) treated with intravenous glucocorticoids (ABLAGO Study)
- Plain-language title
- Comparing two ways to treat an overactive thyroid in Graves' eye diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 19 November 2024